MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity ...

ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells ... cell depletion, typically taking weeks. By engineering immune cells directly ...

That trial, the first randomized, double-blind, placebo-controlled study ever conducted in IgG4-RD, confirmed “beyond doubt” that B-cell depletion ... harmful T cells and by directly secreting ...

expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in vivo CAR T ...

These so-called in vivo cell therapies, if successful ... the multiday or week turnaround typically associated with CAR-T therapy, AstraZeneca said. AstraZeneca intends to use the technology ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to turn its focus toward autoimmune diseases. The move isn’t shocking ...

INB-600 γδ T Cell Engager (TCE) Platform INB-619 is considered a next-generation γδ TCE targeting CD19 which eradicates B ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...

AstraZeneca is buying EsoBiotec for up to $1 billion for the company’s in vivo CAR-T cell drugs, or therapies that reprogram ... a simple IV injection and without the need for immune cell depletion, ...